Progressive Supranuclear Palsy
113
18
28
59
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Research Maturity
59 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.3%
6 terminated out of 113 trials
90.8%
+4.2% vs benchmark
3%
3 trials in Phase 3/4
12%
7 of 59 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 59 completed trials
Clinical Trials (113)
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
Automated Imaging Differentiation of Parkinsonism
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
Gait Analysis in Neurological Disease
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
Neurologic Stem Cell Treatment Study
Trial of Parkinson's And Zoledronic Acid
Research of Biomarkers in Parkinson Disease
Biomarkers in Parkinsonian Syndromes
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
AMX0035 and Progressive Supranuclear Palsy
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
Community Outreach for Palliative Engagement -- Parkinson Disease
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
Art Therapy in Progressive Supranuclear Palsy
The CurePSP Genetics Program